XENICAL 120 MG — DIN 02240325
ORLISTAT : 120 MG · CHEPLAPHARM ARZNEIMITTEL GMBH · CAPSULE · wholesale supply in Canada
Health Canada status: MARKETED
What is XENICAL?
XENICAL 120 MG contains ORLISTAT : 120 MG. It is listed in the Health Canada Drug Product Database under DIN 02240325, held by CHEPLAPHARM ARZNEIMITTEL GMBH, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 01-Jun-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is XENICAL used for?
Obesity management (weight loss/maintenance) and reducing risk of weight regain. For patients with BMI ≥ 30 kg/m2, or ≥ 27 kg/m2 with risk factors (e.g., diabetes, hypertension).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Orlistat cost around the world?
Orlistat is listed on 12 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); Lebanon publishes a public price (USD, Decision 119/1). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Sweden | AIP (pharmacy purchase price) | 4 | 7 | SEK███.██ |
| Norway | max AUP (pharmacy retail) | 2 | 6 | NOK███.██ |
| Saudi Arabia | public | 3 | 6 | SAR███.██ |
| South Africa | single exit price | 3 | 4 | ZAR███.██ |
| Morocco | PPV (public price) | 1 | 2 | MAD███.██ |
| United Arab Emirates | public | 1 | 1 | AED███.██ |
| Australia | ex-manufacturer | 1 | 1 | AUD███.██ |
| United Kingdom | hospital | 1 | 1 | GBP███.██ |
| Greece | producer price (ex-factory) | 1 | 1 | EUR███.██ |
| Lebanon | public price (USD, Decision 119/1) | 1 | 1 | USD███.██ |
| Romania | max producer price | 1 | 1 | RON███.██ |
| United States | acquisition | 1 | 1 | USD███.██ |
32 pack listings across 20 brand entries and 11 price bases, refreshed 08 Sep 2026. Ranges span every Orlistat pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 120 MG |
|---|---|
| Dosage form | CAPSULE |
| Route | ORAL |
| Pack configuration (monograph) | Blister packages in cartons of 84 capsules. |
| Storage | Not explicitly detailed in the provided text snippet (refer to section 11 of full monograph). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Orlistat |
|---|---|
| ATC code | A08AB01 |
| AHFS class | 56:92.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02240325 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2240325 |
| Brand name | XENICAL |
| Generic / active ingredient | ORLISTAT : 120 MG |
| Market authorization holder | CHEPLAPHARM ARZNEIMITTEL GMBH |
| Health Canada schedule | Prescription |
| ATC code | A08AB01 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A08AB |
| Current status | MARKETED |
| Status date | 01-Jun-2018 |
| Original market date | 1999-06-03 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
120 mg three times daily with each main meal (during or up to 1 hour after). Omit dose if meal is missed or contains no fat. Use with a mildly hypocaloric diet (<30% calories from fat).
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Chronic malabsorption syndrome; cholestasis; pregnancy or breast-feeding; hypersensitivity to orlistat or any ingredient in the formulation.
Warnings and precautions
Potential for severe liver injury; increased urinary oxalate/renal failure; risk of GI events with high fat diet; potential for misuse (anorexia/bulimia); monitor for hypoglycemia in diabetics.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC A08AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Orlistat | XENICAL | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A08A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A08AA | Amfepramone · Bupropion And Naltrexone · Fenfluramine · Mazindol · Phentermine · +2 more | 16 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is XENICAL called?
The same molecule, Orlistat, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Xenical® | Latin | Sweden |
| Orlistat Accord | Latin | Norway, Sweden |
| Alli | Latin | South Africa |
| Beacita | Latin | Sweden |
| ORLISTAT | Latin | Lebanon |
| Orlistat STADA | Latin | Sweden |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.